Blueprint Common Stock vs Accounts Payable Analysis

BPMC Stock

USD 107.19 0.19 0.18%

Blueprint Medicines financial indicator trend analysis is way more than just evaluating Blueprint Medicines Corp prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Blueprint Medicines Corp is a good investment. Please check the relationship between Blueprint Medicines Common Stock and its Accounts Payable accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Blueprint Medicines Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.

Common Stock vs Accounts Payable

Common Stock vs Accounts Payable Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Blueprint Medicines Corp Common Stock account and Accounts Payable. At this time, the significance of the direction appears to have very strong relationship.

The correlation between Blueprint Medicines' Common Stock and Accounts Payable is 0.8. Overlapping area represents the amount of variation of Common Stock that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Blueprint Medicines Corp, assuming nothing else is changed. The correlation between historical values of Blueprint Medicines' Common Stock and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock of Blueprint Medicines Corp are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Common Stock i.e., Blueprint Medicines' Common Stock and Accounts Payable go up and down completely randomly.

Correlation Coefficient

0.8

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Common Stock

Accounts Payable

An accounting item on the balance sheet that represents Blueprint Medicines obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Blueprint Medicines Corp are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most indicators from Blueprint Medicines' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Blueprint Medicines Corp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Blueprint Medicines Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.

At present, Blueprint Medicines' Tax Provision is projected to increase significantly based on the last few years of reporting. The current year's Sales General And Administrative To Revenue is expected to grow to 1.12, whereas Issuance Of Capital Stock is forecasted to decline to 0.00.

	2021	2022	2023	2024 (projected)
Interest Expense	7.4M	16.8M	51.6M	54.2M
Depreciation And Amortization	6.5M	11.7M	11.7M	12.2M

Interest Expense Depreciation And Amortization

Blueprint Medicines fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt
Total Assets		0.42	0.07	0.81	0.84	0.48	0.89	0.42	-0.03	-0.68	0.74	0.56	0.88	0.73	0.59	0.78	0.99	0.9	0.94	0.56	-0.52	0.95	0.63	0.83	0.94	0.39
Short Long Term Debt Total	0.42		0.3	0.84	-0.07	0.92	0.52	0.09	0.81	-0.89	0.34	-0.14	0.25	0.86	-0.06	0.12	0.34	0.5	0.53	0.92	0.09	0.56	0.92	0.75	0.48	1.0
Other Current Liab	0.07	0.3		0.15	0.16	-0.07	0.1	-0.85	0.11	-0.1	0.44	0.17	0.23	0.11	0.2	-0.01	0.07	0.15	0.12	-0.06	-0.21	0.08	-0.01	0.14	-0.05	0.26
Total Current Liabilities	0.81	0.84	0.15		0.4	0.85	0.87	0.37	0.53	-0.97	0.67	0.13	0.64	0.98	0.2	0.59	0.75	0.83	0.88	0.9	-0.18	0.9	0.94	0.98	0.82	0.82
Total Stockholder Equity	0.84	-0.07	0.16	0.4		-0.06	0.63	0.17	-0.51	-0.2	0.67	0.78	0.87	0.28	0.77	0.72	0.89	0.67	0.69	0.03	-0.72	0.67	0.12	0.46	0.7	-0.1
Other Liab	0.48	0.92	-0.07	0.85	-0.06		0.54	0.44	0.75	-0.92	0.24	-0.13	0.2	0.89	-0.1	0.21	0.4	0.56	0.58	0.99	0.17	0.61	0.98	0.76	0.6	0.93
Property Plant And Equipment Net	0.89	0.52	0.1	0.87	0.63	0.54		0.41	0.23	-0.8	0.8	0.24	0.79	0.83	0.34	0.81	0.84	0.87	0.93	0.64	-0.27	0.96	0.7	0.93	0.84	0.48
Current Deferred Revenue	0.42	0.09	-0.85	0.37	0.17	0.44	0.41		0.08	-0.38	0.0	-0.03	0.2	0.39	-0.01	0.41	0.39	0.33	0.39	0.47	0.04	0.43	0.45	0.38	0.51	0.1
Net Debt	-0.03	0.81	0.11	0.53	-0.51	0.75	0.23	0.08		-0.67	0.04	-0.7	-0.11	0.62	-0.43	-0.04	-0.13	0.09	0.15	0.73	0.37	0.19	0.7	0.48	0.03	0.81
Retained Earnings	-0.68	-0.89	-0.1	-0.97	-0.2	-0.92	-0.8	-0.38	-0.67		-0.58	0.03	-0.47	-0.99	0.01	-0.49	-0.61	-0.76	-0.8	-0.95	0.01	-0.83	-0.97	-0.94	-0.73	-0.88
Accounts Payable	0.74	0.34	0.44	0.67	0.67	0.24	0.8	0.0	0.04	-0.58		0.36	0.76	0.63	0.21	0.67	0.72	0.79	0.81	0.32	-0.44	0.79	0.41	0.74	0.62	0.3
Cash	0.56	-0.14	0.17	0.13	0.78	-0.13	0.24	-0.03	-0.7	0.03	0.36		0.49	0.01	0.65	0.21	0.64	0.46	0.39	-0.11	-0.51	0.36	-0.05	0.12	0.54	-0.14
Non Current Assets Total	0.88	0.25	0.23	0.64	0.87	0.2	0.79	0.2	-0.11	-0.47	0.76	0.49		0.52	0.7	0.71	0.89	0.68	0.75	0.3	-0.78	0.78	0.39	0.71	0.67	0.21
Non Currrent Assets Other	0.73	0.86	0.11	0.98	0.28	0.89	0.83	0.39	0.62	-0.99	0.63	0.01	0.52		0.04	0.56	0.66	0.79	0.84	0.93	-0.04	0.85	0.96	0.96	0.77	0.84
Other Assets	0.59	-0.06	0.2	0.2	0.77	-0.1	0.34	-0.01	-0.43	0.01	0.21	0.65	0.7	0.04		0.41	0.65	0.31	0.34	-0.05	-0.7	0.36	0.01	0.2	0.43	-0.08
Long Term Debt	0.78	0.12	-0.01	0.59	0.72	0.21	0.81	0.41	-0.04	-0.49	0.67	0.21	0.71	0.56	0.41		0.77	0.74	0.82	0.3	-0.31	0.78	0.37	0.67	0.72	0.08
Cash And Short Term Investments	0.99	0.34	0.07	0.75	0.89	0.4	0.84	0.39	-0.13	-0.61	0.72	0.64	0.89	0.66	0.65	0.77		0.87	0.9	0.48	-0.58	0.9	0.55	0.77	0.92	0.32
Common Stock Total Equity	0.9	0.5	0.15	0.83	0.67	0.56	0.87	0.33	0.09	-0.76	0.79	0.46	0.68	0.79	0.31	0.74	0.87		0.97	0.61	-0.26	0.94	0.67	0.82	0.93	0.49
Common Stock Shares Outstanding	0.94	0.53	0.12	0.88	0.69	0.58	0.93	0.39	0.15	-0.8	0.81	0.39	0.75	0.84	0.34	0.82	0.9	0.97		0.65	-0.3	0.98	0.71	0.89	0.94	0.5
Non Current Liabilities Total	0.56	0.92	-0.06	0.9	0.03	0.99	0.64	0.47	0.73	-0.95	0.32	-0.11	0.3	0.93	-0.05	0.3	0.48	0.61	0.65		0.11	0.68	0.99	0.83	0.65	0.92
Other Current Assets	-0.52	0.09	-0.21	-0.18	-0.72	0.17	-0.27	0.04	0.37	0.01	-0.44	-0.51	-0.78	-0.04	-0.7	-0.31	-0.58	-0.26	-0.3	0.11		-0.35	0.04	-0.2	-0.27	0.11
Other Stockholder Equity	0.95	0.56	0.08	0.9	0.67	0.61	0.96	0.43	0.19	-0.83	0.79	0.36	0.78	0.85	0.36	0.78	0.9	0.94	0.98	0.68	-0.35		0.75	0.91	0.93	0.53
Total Liab	0.63	0.92	-0.01	0.94	0.12	0.98	0.7	0.45	0.7	-0.97	0.41	-0.05	0.39	0.96	0.01	0.37	0.55	0.67	0.71	0.99	0.04	0.75		0.88	0.7	0.91
Property Plant And Equipment Gross	0.83	0.75	0.14	0.98	0.46	0.76	0.93	0.38	0.48	-0.94	0.74	0.12	0.71	0.96	0.2	0.67	0.77	0.82	0.89	0.83	-0.2	0.91	0.88		0.8	0.72
Total Current Assets	0.94	0.48	-0.05	0.82	0.7	0.6	0.84	0.51	0.03	-0.73	0.62	0.54	0.67	0.77	0.43	0.72	0.92	0.93	0.94	0.65	-0.27	0.93	0.7	0.8		0.47
Short Term Debt	0.39	1.0	0.26	0.82	-0.1	0.93	0.48	0.1	0.81	-0.88	0.3	-0.14	0.21	0.84	-0.08	0.08	0.32	0.49	0.5	0.92	0.11	0.53	0.91	0.72	0.47

Click cells to compare fundamentals

Blueprint Medicines Account Relationship Matchups

Blueprint Medicines fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	707.7M	1.7B	1.3B	1.3B	1.0B	784.9M
Short Long Term Debt Total	95.9M	89.6M	111.4M	242.5M	774.1M	812.8M
Other Current Liab	88.7M	105.9M	96.8M	(295.5M)	128.0M	134.4M
Total Current Liabilities	106.5M	130.8M	149.8M	183.2M	214.9M	225.7M
Total Stockholder Equity	464.4M	1.5B	970.7M	514.7M	130.6M	124.1M
Other Liab	47.7M	35.8M	28.4M	437.0M	502.5M	527.6M
Property Plant And Equipment Net	111.1M	101.7M	120.9M	115.2M	115.7M	63.4M
Current Deferred Revenue	6.2M	12.6M	36.6M	448.6M	812K	771.4K
Net Debt	(18.0M)	(595.0M)	(98.5M)	122.7M	702.8M	738.0M
Retained Earnings	(945.2M)	(631.4M)	(1.3B)	(1.8B)	(2.3B)	(2.2B)
Accounts Payable	4.8M	4.4M	8.3M	2.7M	4.7M	3.9M
Cash	113.9M	684.6M	209.9M	119.7M	71.3M	67.7M
Non Current Assets Total	190.9M	790.6M	698.2M	303.3M	240.9M	236.9M
Non Currrent Assets Other	15.4M	11.1M	19.8M	26.8M	30.6M	32.2M
Other Assets	15.4M	569.3M	19.8M	26.8M	1.0	0.95
Cash And Short Term Investments	548.0M	1.5B	1.0B	1.1B	710.6M	656.9M
Common Stock Total Equity	49K	58K	59K	60K	69K	41.4K
Common Stock Shares Outstanding	47.8M	56.2M	58.5M	59.6M	60.6M	43.6M
Liabilities And Stockholders Equity	707.7M	1.7B	1.3B	1.3B	1.0B	784.9M
Non Current Liabilities Total	136.9M	117.5M	131.7M	652.0M	703.7M	738.9M
Other Current Assets	379.4M	(655.9M)	(539.5M)	35.0M	33.4M	35.0M
Other Stockholder Equity	1.4B	2.1B	2.3B	2.4B	2.5B	1.3B
Total Liab	243.3M	248.3M	281.5M	835.2M	918.6M	964.6M
Property Plant And Equipment Gross	111.1M	101.7M	146.3M	146.5M	154.1M	161.9M
Total Current Assets	516.8M	927.8M	554.0M	1.0B	808.4M	548.0M
Accumulated Other Comprehensive Income	(2.5M)	(5.2M)	(4.1M)	(10.4M)	(3.5M)	(3.7M)
Short Term Debt	6.8M	7.9M	8.1M	27.4M	81.4M	85.5M
Common Stock	49K	58K	59K	60K	61K	43.7K
Property Plant Equipment	38.4M	34.1M	30.7M	33.3M	38.3M	22.7M
Net Tangible Assets	464.4M	1.5B	1.2B	514.7M	591.9M	613.2M
Net Receivables	23.4M	25.3M	37.0M	36.9M	43.2M	45.3M
Short Term Investments	369.6M	187.2M	267.2M	825.3M	639.4M	346.5M
Retained Earnings Total Equity	(945.2M)	(631.4M)	(1.3B)	(1.8B)	(1.6B)	(1.6B)
Capital Surpluse	1.4B	2.1B	2.3B	2.4B	2.7B	1.5B

Pair Trading with Blueprint Medicines

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Blueprint Medicines position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Blueprint Medicines will appreciate offsetting losses from the drop in the long position's value.

Moving against Blueprint Stock

0.53	IMCR	Immunocore Holdings Financial Report 8th of May 2024	Pair Corr
0.51	SABSW	SAB Biotherapeutics	Pair Corr
0.46	GILD	Gilead Sciences	Pair Corr
0.44	TXG	10X Genomics	Pair Corr
0.42	EWTX	Edgewise Therapeutics Financial Report 9th of May 2024	Pair Corr

The ability to find closely correlated positions to Blueprint Medicines could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Blueprint Medicines when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Blueprint Medicines - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Blueprint Medicines Corp to buy it.

The correlation of Blueprint Medicines is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Blueprint Medicines moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Blueprint Medicines Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Blueprint Medicines can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Blueprint Medicines Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Blueprint Medicines' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Blueprint Medicines Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Blueprint Medicines Corp Stock:

How To Invest In Blueprint

Details

Is Blueprint Stock a good investment?

Details

What is Blueprint Medicines' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Blueprint Medicines Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.

You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.

Complementary Tools for Blueprint Stock analysis

When running Blueprint Medicines' price analysis, check to measure Blueprint Medicines' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Blueprint Medicines is operating at the current time. Most of Blueprint Medicines' value examination focuses on studying past and present price action to predict the probability of Blueprint Medicines' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Blueprint Medicines' price. Additionally, you may evaluate how the addition of Blueprint Medicines to your portfolios can decrease your overall portfolio volatility.

	Commodity Directory Find actively traded commodities issued by global exchanges
	Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios
	My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
	Share Portfolio Track or share privately all of your investments from the convenience of any device
	Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals

Is Blueprint Medicines' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Blueprint Medicines. If investors know Blueprint will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Blueprint Medicines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(8.37)

Revenue Per Share

4.118

Quarterly Revenue Growth

0.855

Return On Assets

(0.25)

Return On Equity

(1.57)

The market value of Blueprint Medicines Corp is measured differently than its book value, which is the value of Blueprint that is recorded on the company's balance sheet. Investors also form their own opinion of Blueprint Medicines' value that differs from its market value or its book value, called intrinsic value, which is Blueprint Medicines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Blueprint Medicines' market value can be influenced by many factors that don't directly affect Blueprint Medicines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Blueprint Medicines' value and its price as these two are different measures arrived at by different means. Investors typically determine if Blueprint Medicines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Blueprint Medicines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Blueprint Common Stock vs Accounts Payable Analysis

Common Stock vs Accounts Payable

Common Stock vs Accounts Payable Correlation Analysis

Correlation Coefficient

Common Stock

Accounts Payable

Blueprint Medicines fundamental ratios Correlations

Blueprint Medicines Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Blueprint Medicines fundamental ratios Accounts

Pair Trading with Blueprint Medicines

Moving against Blueprint Stock

Complementary Tools for Blueprint Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Short Term Debt	+ 1.0	Short Long Term Debt Total
Cash And Short Term Investments	+ 0.99	Total Assets
Non Current Liabilities Total	+ 0.99	Other Liab
Total Liab	+ 0.99	Non Current Liabilities Total
Non Currrent Assets Other	+ 0.98	Total Current Liabilities
Property Plant And Equipment Gross	+ 0.98	Total Current Liabilities

Non Currrent Assets Other	- 0.99	Retained Earnings
Total Liab	- 0.97	Retained Earnings
Retained Earnings	- 0.97	Total Current Liabilities
Non Current Liabilities Total	- 0.95	Retained Earnings
Property Plant And Equipment Gross	- 0.94	Retained Earnings
Retained Earnings	- 0.92	Other Liab